| 1 |
Skricková J, Kadlec B, Venclícek O. Non-small cell lung cancer[J]. Vnitr Lek, 2018, 63(11): 861-874.
|
| 2 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
|
| 3 |
Huang P, Park S, Yan R, et al. Added value of computer-aided CT image features for early lung cancer diagnosis with small pulmonary nodules: a matched case-control study[J]. Radiology, 2017, 286(1): 286-295.
|
| 4 |
Ilie M, Hofman V, Long-Mira E, et al. "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease[J]. PLoS One, 2014, 9(10): e111597.
|
| 5 |
Mizuno T, Arimura T, Kuroda H, et al. Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer[J]. J Thoracic Dis, 2018, 10(3): 1788-1796.
|
| 6 |
Wang X, Liu H, Shen Y, et al. Low-dose computed tomography (LDCT) versus other cancer screenings in early diagnosis of lung cancer: A meta-analysis[J]. Medicine, 2018, 97(27): e11233.
|
| 7 |
Naidich DP, Marshall CH, Gribbin C, et al. Low-dose CT of the lungs: preliminary observations[J]. Radiology, 1990, 175(3): 729-731.
|
| 8 |
Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomo graphicscreening[J]. N Engl J Med, 2011, 365(5): 395-409.
|
| 9 |
Rocco G, Pennazza G, Santonico M, et al. Breathprinting and early diagnosis of lung cancer[J]. J Thorac Oncol, 2018, 13(7): 883-894.
|
| 10 |
Luo X, Zang X, Yang L, et al. Comprehensive computational pathological image analysis predicts lung cancer prognosis[J]. J Thorac Oncol, 2017, 12(3): 501-509.
|
| 11 |
Jin X, Zhao SH, Gao J, et al. CT characteristics and pathological implications of early stage(T1N0M0)lung adenocarcinoma with pure ground-glass opacity[J]. Eur Radiol, 2015, 25(7): 2532-2540.
|
| 12 |
Eguchi T, Yoshizawa A, Kawakami S, et al. Tumor size and computed tomography attenuation of pulmonary pure ground-glass nodules are useful for predicting pathological invasiveness[J]. PLo S One, 2014, 9: e97867.
|
| 13 |
Eguchi T, Kondo R, Kawakami S, et al. Computed tomography attenuation predicts the growth of pureground-glass nodules[J]. Lung Cancer, 2014, 84: 242-247.
|
| 14 |
Lim HJ, Ahn S, Lee KS, et al. Persistent pure groundglass opacity lung nodules>/＝10 mm in diameter at CT scan：histopathologic comparisons and prognostic implications[J]. Chest, 2013, 144: 1291-1299.
|
| 15 |
Matthews AK, McCabe SE, Lee JGL, et al. Differences in smoking prevalence and eligibility for low-dose computed tomography (LDCT) lung cancer screening among older U．S. adults: role of sexual orientation[J]. Cancer Causes Control, 2018, 29(8): 769-774.
|
| 16 |
Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5): 395-409.
|
| 17 |
Doss M. Adoption of linear no-threshold model violated basic scientific principles and was harmful: Letter from Mohan Doss regarding Edward Calabrese′s paper "ow the US National Academy of Sciences misled the world community on cancer risk assessment: new findings challenge historical foundations of the linear dose response" (Arch Toxicol (2013) 87: 2063-2081) and the letter from Ralph J Cicerone (Arch Toxicol (2014) 88：171-172)[J]. Arch Toxicol, 2014, 88(3): 849-852.
|
| 18 |
Chung K, Mets OM, Gerke PK, et al. Brock malignancy risk calculator for pulmonary nodules: validation outside a lung cancer screening population[J]. Thorax, 2018, 73(9): 857-863.
|
| 19 |
Paul R, Hawkins SH, Schabath MB, et al. Predicting malignant nodules by fusing deep features with classical radiomics features[J]. J Med Imaging (Bellingham), 2018, 5(1): 011021.
|
| 20 |
Jett J. Screening for lung cancer: Who should be screened？[J]. Arch Pathol Lab Med, 2012, 136(12): 1511-1514.
|
| 21 |
Toyoda Y, Nakayama T, Kusunoki Y, et al. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography[J]. Br J Cancer, 2008, 98(10): 1602-1607.
|
| 22 |
Marcus PM, Bergstrah EJ, Zweig MH, et al. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis[J]. J Natl Cancer Inst, 2006, 98(11): 748-756.
|
| 23 |
Toyoda Y, Nakayama T, Kusunoki Y, et al. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography[J]. Br J Cancer, 2008, 98(10): 1602-1607.
|
| 24 |
Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer，version 6.2015[J]. J Nat Compr Cancer Netw, 2015, 13(5): 515-524.
|
| 25 |
Hüsemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer[J]. Cancer Cell, 2008, 13(1): 58-68.
|
| 26 |
Kim P, Lee JK, Lim OK, et al. Quantitative lymphoscintigraphy to predict the possibility of lymphedema development after breast cancer surgery: retrospective clinical study[J]. Ann Rehabil Med, 2017, 41(6): 1065-1075.
|
| 27 |
Miller MC, Doyle GV. Significance of circulating tumorcells detected by the cell search system in patients with me-tastatic breast colorectal and prostate cancer[J]. J Oncol, 2009, 2010: 617-625.
|
| 28 |
Mohamadi RM, Besant JD, Mepham A, et al. Nanoparticle-mediated binning and profiling of heterogeneous circulating tumor cell subpopulations[J]. Angew Chem Int Ed Engl, 2015, 54(1): 139-143.
|
| 29 |
Zhang H, Jia Z, Wu C, et al. In vivo capture of circulating tumor cells based on transfusion with a vein indwelling needle[J]. ACS Appl Mater Interfaces, 2015, 7(36): 20477-20484.
|
| 30 |
Michal Mego, James M Reuben. Prognostic and predictive role of circulating tumor cells in breast cancer[J]. Current Breast Cancer Reports, 2014, 6(4): 251-259.
|
| 31 |
Liu X, Li C, Li J, et al. Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer[J]. J Cancer, 2018, 9(11): 2038-2045.
|
| 32 |
Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulatingtumor cells to tumor response, progression-free survival, and over-all survival in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(19): 3213-3221.
|
| 33 |
Muinelo-Romay L, Vieito M, Abalo A, et al. Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment[J]. Cancers(Basel), 2014, 6: 153-165.
|
| 34 |
Khoja L, Backen A, Sloane R, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker[J]. Br J Cancer, 2012, 106(3): 508-516.
|
| 35 |
Went PT, Lugli A, Meier S, et al. Frequent EpCAM protein expression in human carcinomas[J]. Hum Pathol, 2004, 35: 122-128.
|
| 36 |
Takao M, Takeda K. Enumeration, characterization, and collection of intact circulating tumor cells by cross contamination-free flow cytometry[J]. Cytometry A, 2011, 79(2): 107-117.
|
| 37 |
Alix-Panabières C, Pantel K. Challenges in circulating tumour cell research[J]. Nat Rev Cancer, 2014, 14(9): 623-631.
|
| 38 |
Abhisek M, Lopa M, Shulin L, et al. EMT, CTCs and CSCs in tumor relapse and drug-resistance[J]. Oncotarget, 2015, 6(13): 10697-10711.
|
| 39 |
Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer：diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(5): 142-165.
|
| 40 |
Steinbichler TB, Dudás J, Riechelmann H, et al. The role of exosomes in cancer metastasis[J]. Semin Cancer Biol, 2017, 44: 170-181.
|
| 41 |
Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patientswith stage I lung cancer detected on CT screening[J]. N Engl J Med, 2006, 355: 1763-1771.
|
| 42 |
Riahi R, Gogoi P, Sepehri S, et al. A novel microchannel-based device to capture and analyze circulating tumor cells (ctcs) ofbreast cancer[J]. Int J Oncol, 2014, 44(6):1870-1878.
|
| 43 |
Salis F, Descalzo AB, Benito-Peña E, et al. Highly fluorescent magnetic nanobeads with a remarkable stokes shift as labels for enhanced detection in immunoassays[J]. Small, 2018, 14(20): e1703810.
|